Sightera Biosciences
AI-Powered Drug Discovery
About Sightera Biosciences
Sightera Biosciences is a Belgian AI-native biotech company founded in 2025 as a spin-off from the University of Antwerp and Antwerp University Hospital.
The company is developing a next-generation drug discovery platform that combines generative AI with proprietary patient-derived biological data to design first-in-class small molecules for oncology and fibrosis.
Rather than relying on public datasets, Sightera trains its AI models on clinically correlated drug-response data generated from advanced translational ex vivo systems and high-throughput robotic screening of treatment-resistant patient samples.
The company’s discovery pipeline currently includes three lead programmes, SIGHT001 and SIGHT002 for cancer, along with SIGHT101 for fibrotic diseases, while also advancing a platform for novel antibody-drug conjugate (ADC) payloads. Its flagship SIGHT001 programme focuses on biomarker-selected gastrointestinal solid tumours using AI-designed molecular glue technology engineered for heavily pre-treated patients and combination therapies.
Founders
Funding History
Frequently Asked Questions
What does Sightera Biosciences do?
Sightera Biosciences is an AI-native biotech company that combines patient-derived biological data with generative AI to discover and design novel small-molecule therapies, initially focusing on oncology and fibrosis.
When was Sightera Biosciences founded?
The company was incorporated on 9 January 2025 and later spun out from the University of Antwerp and Antwerp University Hospital in 2026.
Who founded Sightera Biosciences?
Sightera Biosciences was founded by Hendrik Vercammen (CEO), Maxim Le Compte (CSO), Christophe Deben (CDO), and Lars Vanlommel (CBO).
How much funding has Sightera Biosciences raised?
The company has publicly disclosed approximately €3.05 million in funding, including a €50,000 Vlerick Entrepreneurship Fund prize in November 2024 and a €3 million Pre-Seed round announced on 17 July 2026.
What is Sightera Biosciences' valuation?
Sightera Biosciences has not publicly disclosed its valuation following any funding round.
What makes Sightera's AI platform different?
Unlike many AI drug discovery companies that rely on public datasets, Sightera trains its AI models using proprietary, clinically correlated, patient-derived drug-response data to improve the identification of first-in-class therapeutic candidates.
